 YONKERS, N.Y., Feb. 10, 2022 GLOBE NEWSWIRE -- ContraFect Corporation Nasdaq: CFRX, a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents DLAs, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that Roger Pomerantz, M.D., President, Chief Executive Officer and Chairman of ContraFect, will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference, which is being held virtually from February 1418, 2022. The fireside chat will be held on Thursday, February 17, 2022 at 10:00 AM ET. 